Effects of Polyphenolic-rich Dark Chocolate/Cocoa and Almonds on Cardiovascular Disease Risk Factors
- Conditions
- Cardiovascular Disease
- Registration Number
- NCT01882881
- Lead Sponsor
- Penn State University
- Brief Summary
- The purpose of this study is to investigate the individual and combined effects of dark chocolate/cocoa and almonds on lipids, lipoproteins, antioxidant defense, lipid peroxidation, phenolic acids, inflammatory status, blood pressure and arterial health. It is hypothesized that dark chocolate/cocoa and/or almonds will favorably affect lipids, lipoproteins, antioxidants, inflammatory status, blood pressure and arterial health compared to a healthy American control diet; however, the effects will be greater when dark chocolate/cocoa and almonds are consumed together versus consumption of each food individually. 
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
- Overweight and obese (BMI ≥25, ≤40 kg/m2)
- Moderately elevated LDL-C between the 25-95th percentile from NHANES:
105-194 mg/dL for males; 98-190 mg/dL for females.
- Tobacco use
- Systolic blood pressure ≥159 mm Hg
- Diastolic blood pressure ≥ 99 mm Hg
- A history of myocardial infarction, stroke, diabetes mellitus, liver disease, kidney disease, and thyroid disease (unless controlled on meds)
- Blood pressure or cholesterol-lowering medication use
- Refusal to discontinue intake of putative cholesterol-lowering supplements (e.g. psyllium, fish oil, soy lecithin, niacin, fiber, flax, stanols/sterols)
- Vegetarianism or dietary practices that are inconsistent with the test diets
- Nut allergies
- Refusal to discontinue nutritional supplements, herbs, or vitamins
- History of inflammatory gastrointestinal disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
- Name - Time - Method - Lipoprotein class and subclass change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - The VAP© Test provides a direct measure of the following lipid and lipoprotein classes and subclasses: LDL, Lp(a), IDL, LDL1, LDL2, LDL3, LDL4, HDL, HDL2, HDL3, VLDL, VLDL1+2, VLDL3, TC, TG, Non-HDL, Remnant Lipoproteins, ApoB100, and ApoA1. - Flow-mediated dilation change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - Lipid/lipoprotein change (standard panel) - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - Total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides - 24-hour ambulatory blood pressure change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) 
- Secondary Outcome Measures
- Name - Time - Method - Plasma flavonoid change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - Serum C-reactive protein change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - LDL oxidation potential change (plasma) - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - The ex vivo resistance of LDL to Cu2+-mediated oxidation will be determined. - Serum insulin change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - Serum glucose change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - Urinary F2α-isoprostane change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) - Plasma tocopherol change - 0 wk, 4 wk, 10 wk, 16 wk, and 22 wk (at baseline and after each of the 4 diet periods) 
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
- Penn State Clinical Research Center, Noll Lab 🇺🇸- University Park, Pennsylvania, United States Penn State Clinical Research Center, Noll Lab🇺🇸University Park, Pennsylvania, United States
